Status:
RECRUITING
HO-1/CREB3 Modulates Golgi Stress in Patients With Sepsis
Lead Sponsor:
Tianjin Nankai Hospital
Conditions:
Sepsis
Eligibility:
All Genders
18-100 years
Brief Summary
This study was an ambispective observational cohort study that included sepsis patients hospitalized in the Intensive care unit (ICU) of the Nankai Hospital. All patients met the consensus criteria of...
Detailed Description
All patients met the consensus criteria of sepsis-3. The purpose of this study is to investigate the valuable biomarkers for the severity of sepsis and predictors of 30-day mortality for patients with...
Eligibility Criteria
Inclusion
- Males or females over the age of 18;
- Sepsis was diagnosed within 48h which meets SPESIS 3 criteria;
- Capable of understanding the purpose and risk of the study;
- Patients or proxy must give written informed consent before any assessment is performed.
Exclusion
- Pregnancy, lactation or perinatal period;
- Breast carcinoma;
- HIV seropositive or Syphilis seropositive;
- Any clinical-relevant condition that might affect study participation and/or study results;
- Participation in any other intervention trial;
- Unwillingness or inability to following the study protocol in the investigators opinion.
Key Trial Info
Start Date :
September 15 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 15 2024
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT06045780
Start Date
September 15 2023
End Date
November 15 2024
Last Update
July 30 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tianjin Nankai Hospital
Tianjin, Tianjin Municipality, China, 300000